

INVITROGEN CORP  
Form 8-K/A  
April 24, 2002

[QuickLinks](#) -- Click here to rapidly navigate through this document

# SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

## FORM 8-K/A

### CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): April 5, 2002

## INVITROGEN CORPORATION

---

(Exact name of registrant as specified in its charter)

**Delaware**

**0-25317**

**33-0373077**

---

(State or other jurisdiction of  
incorporation)

(Commission File No.)

(IRS Employer Identification  
No.)

**1600 Faraday Avenue, Carlsbad, CA**

**92008**

---

(Address of principal executive offices)

(Zip Code)

Registrant's telephone number, including area code: **(760) 603-7200**

---

This Form 8-K/A amends the Form 8-K filed by Invitrogen Corporation on April 9, 2002.

#### Item 4. CHANGES IN REGISTRANT'S CERTIFYING ACCOUNTANT.

Effective April 5, 2002, Invitrogen Corporation (the "Company"), a Delaware corporation, terminated the engagement of Arthur Andersen LLP as its independent auditor. The decision to terminate the engagement of Arthur Andersen was recommended by the Company's Audit Committee and approved by its Board of Directors.

Arthur Andersen's report on the financial statements of the Company for each of the years ended December 31, 2000, and December 31, 2001, did not contain an adverse opinion or a disclaimer of opinion and was not qualified or modified as to uncertainty, audit scope or accounting principles.

During the years ended December 31, 2000, and December 31, 2001, and the interim period between December 31, 2001, and April 5, 2002, there were no disagreements between the Company and Arthur Andersen on any matter of accounting principles or practices, financial statement disclosure or auditing scope or procedure, which disagreements, if not resolved to the satisfaction of Arthur Andersen, would have caused it to make reference to the subject matter of the disagreements in connection with its report. During the years ended December 31, 2000, and December 31, 2001, and the interim period between December 31, 2001, and April 5, 2002, there were no reportable events (as defined in Item 304(a) (1) (v) of Regulation S-K promulgated by the Securities and Exchange Commission). A letter from Arthur Andersen is attached as Exhibit 16.1 to this Report.

The Company has engaged Ernst & Young LLP as its new independent auditor, effective April 5, 2002.

**Item 7. FINANCIAL STATEMENTS AND EXHIBITS.**

(c)  
Exhibits

<b>Exhibit Number</b>	<b>Description of Exhibit</b>
16.1	Letter of Arthur Andersen LLP regarding change in certifying accountant.*
99.1	Press Release, dated April 8, 2002.*

\*  
Previously filed on April 9, 2002 as an exhibit to the Form 8-K.

2

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**Invitrogen Corporation**

Date: April 23, 2002

By: /s/ JOHN A. COTTINGHAM

---

John A. Cottingham  
Vice President, General Counsel and Secretary

---

**EXHIBIT INDEX**

<b>Exhibit</b>	<b>Description</b>
16.1	Letter of Arthur Andersen LLP regarding change in certifying accountant*
99.1	Press Release, dated April 8, 2002*

\*  
Previously filed on April 9, 2002 as an exhibit to the Form 8-K.

QuickLinks

SIGNATURES  
EXHIBIT INDEX